Insider Selling: Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $326,509.26 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Intellia Therapeutics Stock Down 3.6 %

Shares of NTLA opened at $12.02 on Friday. Intellia Therapeutics, Inc. has a 12 month low of $11.34 and a 12 month high of $34.87. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -2.21 and a beta of 1.83. The company has a 50-day moving average price of $13.87 and a two-hundred day moving average price of $19.10.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. During the same period in the prior year, the firm earned ($1.38) EPS. Intellia Therapeutics’s quarterly revenue was down 24.1% compared to the same quarter last year. Equities research analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently made changes to their positions in NTLA. State Street Corp boosted its position in Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after buying an additional 780,754 shares in the last quarter. Patient Square Capital LP acquired a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $2,642,000. Dimensional Fund Advisors LP grew its position in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock worth $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Intellia Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock valued at $17,006,000 after purchasing an additional 37,714 shares in the last quarter. Finally, Verition Fund Management LLC raised its position in Intellia Therapeutics by 116.3% in the 3rd quarter. Verition Fund Management LLC now owns 94,426 shares of the company’s stock valued at $1,940,000 after purchasing an additional 50,763 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

NTLA has been the subject of several analyst reports. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, November 18th. Chardan Capital boosted their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Canaccord Genuity Group reissued a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Barclays reduced their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, Robert W. Baird lowered their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.